Old Web
English
Sign In
Acemap
>
authorDetail
>
Bo-An Li
Bo-An Li
Chinese PLA General Hospital
Medicine
Sorafenib
CYP3A4
Hepatocellular carcinoma
Cancer research
4
Papers
34
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
MDM2 Binding Protein Induces the Resistance of Hepatocellular Carcinoma Cells to Molecular Targeting Agents via Enhancing the Transcription Factor Activity of the Pregnane X Receptor
2021
Frontiers in Oncology
Qiyu Jiang
Yan Ma
Jingjing Han
Jingdong Chu
Xuemei Ma
Lijun Shen
Bo Liu
Bo-An Li
Jun Hou
Qian Bi
Show All
Source
Cite
Save
Citations (4)
The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data.
2021
Journal of Clinical Laboratory Analysis
Bo Li
Ai-Xia Liu
Yi Wen
Guang Yang
Jing Zhao
Xiaohan Li
Yuan-Li Mao
Bo-An Li
Show All
Source
Cite
Save
Citations (1)
Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4.
2021
Frontiers in Oncology
Xi He
Huiwei Sun
Qiyu Jiang
Yantao Chai
Xiaojuan Li
Zhijie Wang
Bing Zhu
Shaoli You
Bo-An Li
Junfeng Hao
Shaojie Xin
Show All
Source
Cite
Save
Citations (2)
Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19.
2020
The Journal of Allergy and Clinical Immunology: In Practice
De Chang
Peng Zhao
Dawei Zhang
Jing-Hui Dong
Zhe Xu
Guang Yang
Bo-Yu Li
Hongxia Liu
Bo-An Li
Cheng-Feng Qin
Xiaohua Peng
Fusheng Wang
Lixin Xie
Zhu Chen
Charles S. Dela Cruz
Lokesh Sharma
Enqiang Qin
Show All
Source
Cite
Save
Citations (27)
1